Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $123M | $170M | $260M |
| Revenue growth | — | 38.3% | 53.2% |
| Gross profit | $70.0M | $103M | $171M |
| Gross margin | 57.0% | 60.6% | 65.7% |
| Operating income | -$66.0M | -$43.7M | -$12.0M |
| Operating margin | -53.8% | -25.7% | -4.6% |
| Net income | -$67.5M | -$47.1M | -$12.8M |
| Net margin | -55.0% | -27.8% | -4.9% |
| EPS (diluted) | -$9.52 | -$6.11 | -$0.35 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$49.7M | -$34.2M | $18.3M |
| Capital expenditures | $416K | $596K | $1.32M |
| Free cash flow | -$50.2M | -$34.8M | $16.9M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $116M | $76.4M | $222M |
| Total assets | — | $151M | $305M |
| Total liabilities | — | $86.3M | $75.7M |
| Long-term debt | — | $29.8M | $0.00 |
| Shareholders' equity | -$350M | -$384M | $230M |
| Retained earnings | — | -$444M | -$457M |
| Shares (wtd avg diluted) | 7.09M | 7.72M | 36.6M |
Every figure is extracted from Omada Health, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.